Search company, investor...
Search
Veloxis Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

veloxis.com

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Veloxis Pharmaceuticals

Veloxis develops a clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water-solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). The company's clinical pipeline currently focuses on cardiovascular disease and immunosuppression.On March 4th, 2020, Veloxis Pharmaceuticals was acquired by Asahi Kasei.3B.

Veloxis Pharmaceuticals Headquarters Location

Agern Alle 24 Bygning 4, 2. sal

Hoersholm, DK-2970,

Denmark

+ 45 70 33 33 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Veloxis Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Veloxis Pharmaceuticals is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Veloxis Pharmaceuticals Patents

Veloxis Pharmaceuticals has filed 34 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Pharmacokinetics
  • Immunosuppressants
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/13/2018

8/23/2022

Dosage forms, Carboxylic acids, Chelating agents, Drug delivery devices, Food additives

Grant

Application Date

11/13/2018

Grant Date

8/23/2022

Title

Related Topics

Dosage forms, Carboxylic acids, Chelating agents, Drug delivery devices, Food additives

Status

Grant

Latest Veloxis Pharmaceuticals News

OSE Immunotherapeutics : 22/09/2022 OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results

Sep 22, 2022

09/22/2022 | 12:10pm EDT Message : Corporate Alexis Vandier appointed new Chief Executive Officer to guide the Company through its next phase of growth Strategy focused on leveraging both the Company's clinical portfolio of first-in-class assets in immuno-oncology and immuno-inflammation along with its two unique pioneering pre-clinical platforms Newly formed international Scientific Advisory Board Pipeline Tedopi® (T-cell specific immunotherapy) - New clinical advances and analyses presented at ASCO and ESMO 2022 €10 million milestone payment received from Boehringer Ingelheim for the initiation of the Phase 1 clinical expansion trial of BI 765063, SIRPα antagonist monoclonal antibody, in advanced hepatocellular carcinoma and head and neck cancer patients €5 million milestone payment received from Veloxis Pharmaceuticals, Inc., for CD28 antagonist VEL-101/FR104 following acceptance of the US Investigational New Drug (IND) Application Financials €16 million turnover and €31 million available cash as of June 30, 2022, providing financial visibility until Q3 2023 Conference call with live webcast on September 23rd at 2:00 p.m. CET / 8:00 a.m. ET. Nantes, France - September 22nd, 2022, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), an integrated biotech company focused on developing first- in-class assets targeting cancer and inflammatory diseases, today provides updates on key milestones achieved during H1 2022 and reports its consolidated half-year financial results as of June 30, 2022. Alexis Vandier, Chief Executive Officer of OSE Immunotherapeutics, comments: "It is a great honor to have joined OSE Immunotherapeutics as Chief Executive Officer. OSE is at the forefront of the science needed to develop first-in-classassets to break the efficacy ceiling of immunotherapeutics targeting immuno-oncology(IO) and immuno-inflammation(I&I) indications. In the first half of 2022, we have continued to make important progress, including with our most advanced product Tedopi®, which had demonstrated positive results in a Phase 3 trial in Non-SmallCell Lung Cancer (NSCLC) patients in secondary resistance after checkpoint inhibitor failure. We intend to further leverage this lead asset Tedopi® in NSCLC and in other cancer indications explored in partnership with clinical oncology groups, both as a monotherapy and in combination. We continue to focus our research efforts on developing next-generationfirst-in-class therapies from our unique proprietary drug discovery platforms to generate significant value: the BiCKI® platform focused on immuno- oncology, and its most advanced BiCKI® candidate targeting anti-PD1xIL-7; and the Myeloid platform, focused on optimizing the therapeutic potential of myeloid cells in IO and I&I where our most advanced preclinical product, OSE-230, has the potential to resolve chronic inflammation. We have also seen important progress in the first half of 2022 with our partnered products. This has resulted in OSE Immunotherapeutics receiving a €10 million milestone payment from Boehringer Ingelheim for the initiation of the Phase 1 clinical expansion trial of BI 765063 in advanced hepatocellular carcinoma and head and neck cancer patients and a further €5 million milestone payment from Veloxis Pharmaceuticals, Inc., for FR104, a CD28 antagonist, following US Investigational New Drug (IND) acceptance for kidney transplant immunosuppression. I am very confident that the globally advanced clinical pipeline that we have today addressing high medical unmet needs, as well as our pioneering platforms, will allow us to deliver on our ambitious goals, and ultimately to improve the lives of patients with cancer and inflammatory diseases." CORPORATE GOVERNANCE - NEW CHIEF EXECUTIVE OFFICER (CEO) AND SCIENTIFIC ADVISORY BOARD (SAB) Appointment of Alexis Vandier as CEO Alexis Vandier was appointed CEO of OSE Immunotherapeutics, effective July 13, 2022. Mr. Vandier brings more than 20 years of experience with extensive international management and leadership experience in the pharmaceutical industry. He joins OSE Immunotherapeutics from Ipsen, where he latest served as Vice-President Global Asset Lead, heading their efforts to build a leading oncology platform. As CEO, Mr. Vandier will lead OSE's corporate, business and development strategy focused on maximizing the value potential of the Company's lead clinical assets, including its ongoing partnered clinical programs and its two proprietary drug discovery platforms BiCKI® and Myeloid. A newly formed SAB combining the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy The SAB, appointed in June 2022, will work with the Company's leadership team and advise its Board of Directors on its scientific, medical, translational and developmental strategy. The SAB includes Pr. Wolf-Hervé Fridman (Université de Paris), Dr. Sophie Brouard (CRTI, Nantes), Dr. Bernard Malissen (CIML, Marseille), Pr. Miriam Merad (Mount Sinai, New-York), Pr. Charles Serhan (Harvard, Boston) and Dr. Jennifer Wargo (MD Anderson Cancer Center, Houston). STRATEGY UPDATE The Company pursues the ambition "to become a fast-growing biotech company combining a clinical portfolio of first-in-class assets in immuno-oncology and immuno-inflammation with a unique pioneering, highly productive pre-clinical platform engine." OSE Immunotherapeutics is in a unique position to achieve this ambitious goal based on its: Ability to master complex biology, particularly with regards to T-cells and myeloid cells and their ability to improve the treatment of IO and I&I indications, Strong clinical development expertise and Well-balancedclinical portfolio of wholly owned and partnered assets. The Company is continuing to focus significant resources on Tedopi®, its most advanced asset and is working diligently to ensure it can start an additional Phase 3 study, in NSCLC patients with secondary resistance after failure with a first line immune checkpoint inhibitor treatment. The Company is further preparing a submission for early access to make this treatment available for patients with a high unmet medical need as soon as possible. Beyond use in monotherapy, Tedopi® is being developed in combination in several phase 2 trials led by clinical oncology groups. OSE Immunotherapeutics will also continue to support its partners, Boehringer Ingelheim, Servier and Veloxis, to ensure their assets can progress into late-stage clinical trials. In parallel, OSE Immunotherapeutics expects to be able to generate further significant value from its two proprietary drug discovery platforms: BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform relying on the proprietary anti-PD1 backbone (OSE-279) to increase anti-tumor efficacy. The most advanced BiCKI® candidate is targeting anti-PD1xIL-7. Myeloid platform, which is focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity. MAJOR CLINICAL PROGRESS IN IMMUNO-ONCOLOGY AND IMMUNO-INFLAMMATION TEDOPI®, a T-cell specific immunotherapy: Positive clinical results and analyses shared at the American Society of Clinical Oncology (ASCO) and at the European Society for Medical Oncology (ESMO) annual meetings ASCO (June 2022) In advanced HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors, final data of Phase 3 Atalante-1 randomized trial were presented by Prof. Benjamin Besse (Gustave Roussy Institute, Villejuif, France). This presentation featured final positive Patient Reported Outcomes (PROs) significantly better with Tedopi® than with chemotherapy in the primary analysis for the population of interest (n=118 patients), defined as NSCLC patients in secondary resistance after checkpoint inhibitor failure. These PROs results and secondary endpoints were also confirmed as significant in the global population as sensitivity analysis (n=219 patients). In advanced pancreatic ductal adenocarcinoma, a randomized non-comparative Phase II study of maintenance with Tedopi®, in monotherapy or in combination with nivolumab, or FOLFIRI after induction with FOLFIRINOX was presented by Dr. Anthony Turpin (Lille University Hospital, Lille, France). This presentation featured the first interim results from this Phase 2 clinical trial of Tedopi® in advanced or metastatic pancreatic cancer. The primary endpoint of the trial is the one-year survival rate (Fleming- futility analysis; null hypothesis <25%), and the key secondary endpoint was the Time to maintenance Strategy Failure (TSF= time maintenance + FOLFIRI reintroduction). The GERCOR oncology clinician group and the PRODIGE Intergroup, are sponsors of this study named TEDOPaM. ESMO (September 2022) A first analysis compared Tedopi® to the Standard of Care (SoC) in patients with advanced NSCLC after secondary resistance to sequential use of chemotherapy followed by immunotherapy (CT-IO). The results have shown that in advanced HLA-A2+ NSCLC patients with IO secondary resistance after sequential CT-IO (n=118), overall survival (OS) was longer with Tedopi® versus SoC regardless of the use (or not) of post progression anticancer treatment (with 13.5 months versus 10.6, HR=0.71; without 6.3 months versus 4.5, HR=0.76). A second analysis assessed the overall benefit/risk of Tedopi® versus SoC chemotherapy in patients with NSCLC who failed therapy with immune checkpoint inhibitors. The Net Treatment Benefit (NTB), a new statistical method combining efficacy, safety and quality of life, was assessed in the overall population (n=219). NTB of Tedopi® was of 19% and reached statistical significance (p=0.035). BI 765063, a myeloid checkpoint inhibitor being developed in partnership with Boehringer Ingelheim In May 2022, the initiation of the Phase 1 clinical expansion trial with BI 765063 sponsored and conducted by Boehringer Ingelheim triggered a €10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics. The trial is being conducted in advanced hepatocellular carcinoma and head and neck cancer patients in combination, in particular with anti-PD-1 antibody ezabenlimab. VEL-101/FR104, a monoclonal antibody antagonist of CD28 developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation In January 2022, Veloxis obtained acceptance of the IND from the Food & Drug Administration (FDA) for a clinical trial with VEL-101/FR104 sponsored and conducted by Veloxis in the US. Based on the global license agreement signed in April 2021, this first milestone triggered a €5 million payment from Veloxis to OSE Immunotherapeutics. In February 2022, Veloxis obtained Fast Track Designation from the FDA for VEL-101/FR104 being developed for prophylaxis of renal allograft rejection in recipients of kidney transplants. In May 2022, dosing of the first participant in the Phase 1 occurred. CoVepiT, a prophylactic vaccine candidate against COVID-19: Positive long-term immune T cell memory responses In March 2022, positive long term immunological results at 6 months induced by CoVepiT in healthy volunteers with strong T cell memory responses against virus proteins were announced. In parallel, the resolution of local indurations related to T cell mechanism of action and the good safety profile were confirmed. However, new treatments like monoclonal antibodies or anti-viral treatments and new vaccines covering emerging variants are already available for targeted immunocompromised patients. Given these new therapeutic alternatives and multiple boosters recommended for these patients, additional clinical development of CoVepiT is made difficult. The Company's strategy is now to select the most relevant peptides allowing for an easier industrial scale-up to be ready at the request of Health Authorities for any new pandemic crisis with a novel variant. R&D PROGRAMS IN IMMUNOTHERAPY BiCKI®-IL-7, a novel bispecific therapy combining anti-PD-1 and the cytokine IL-7 Presentation at the American Association for Cancer Research (AACR) in April 2022: Update on the advancements made with BiCKI®-IL-7 in an oral session dedicated to an overview of the novel trends in cytokine immunotherapy. This presentation highlighted the differentiation of the novel bispecific therapy combining anti-PD1 and IL-7 cytokine and positioned it as a high potential asset for cancer patients suffering from immune escape following checkpoint inhibitor treatments. New myeloid checkpoint target CLEC-1* (a C type lectin receptor) and first monoclonal antibody antagonists of CLEC-1 blocking the "Don't Eat Me" signal Presentations at the Immuno-Oncology Summit Europe in May 2022 and Tumor Myeloid-Directed Therapies Summit in June 2022: CLEC-1,a novel checkpoint to regulate the antigen cross-presentation properties of dendritic cells. The identification and validation of novel immune checkpoint targets and development of their antagonists as an innovation in cancer immunotherapy to enhance myeloid cells and promote antigen presentation to bridge the innate and adaptative immune system. How the SIRPα-CD47 axis stimulates macrophages to recruit the adaptive immune arm via chemoattraction, and inhibition of this pathway may avoid T cell exclusion in synergy with T cell immune checkpoint and clinical translation. *Collaborative program between OSE Immunotherapeutics and Dr Elise Chiffoleau's ( https://cr2ti.univ- nantes.fr/research/team-1 ) research teams (Center for Research in Transplantation and Translational Immunology (CR2TI), UMR1064, INSERM, Nantes University at Nantes University Hospital). A strong intellectual property (IP) with a broad scope to strengthen candidates' position in our portfolio Three new patents granted: in January 2022, a Japanese patent for use of Tedopi® after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients, until 2037; in March 2022, a US patent for OSE-279 and its use in cancer treatment, until 2039; in May 2022, a European patent covering CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy, until 2037. H1 2022 RESULTS

  • Where is Veloxis Pharmaceuticals's headquarters?

    Veloxis Pharmaceuticals's headquarters is located at Agern Alle 24, Hoersholm.

  • What is Veloxis Pharmaceuticals's latest funding round?

    Veloxis Pharmaceuticals's latest funding round is Acq - P2P.

  • Who are the investors of Veloxis Pharmaceuticals?

    Investors of Veloxis Pharmaceuticals include Asahi Kasei, Alta Partners and Novo Holdings.

  • Who are Veloxis Pharmaceuticals's competitors?

    Competitors of Veloxis Pharmaceuticals include Aura Biosciences, PolyPid, Sol-Gel, MicroCHIPS Biotech, OptiNose and 12 more.

You May Also Like

C
Capsutech

CapsuTech is a product driven company focused on research and development of semi-natural, peptide-based, polymers for drug targeting and encapsulation of various chemical and biological entities. Such entities might be drugs, cosmetics, vitamins, food additives, proteins, virions and even cells.nVarious combinations of CapsuTech's modified amino-acid building-blocks provide high-diversity population of polymers and thus enable to formulate almost all molecules and to meet wide spectrum of needs. Such needs include targeting, site-specific release, controlled release. Other characteristics include protection from pH, enzyme proteolysis, oxidation, light and other damaging factors.

N
Next Breath

Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.

O
Optotrack

Optotrack, Inc. is a high-tech company leading in the research and development of optical, imaging, chemical, as well as biological sensors and microsystems. The company is dedicated to commercializing its intellectual properties based on microfabrication and nanotechnology to seize rapidly growing market opportunities in the industries of healthcare, communication, and homeland security. Optotrack, Inc. offers a broad range of technology and business solutions from design through production to marketing and sales. The company combine decades of industry experience and R&D expertise in thin-film science, polymer engineering, solid-state sensing, digital imaging, optoelectronics, RF circuitry, medical diagnostics, microfluidics, and drug delivery to provide enabling technologies to the company's partners, customers, and community. The firm aims to deliver products and services of exceptional quality to cast the future, to improve the life quality for everyone.

E
Eratech srl

Eratech is a drug development company specialized in the field of inhalation drug delivery via nasal and pulmonary administration, for local and systemic therapies. Eratech offers to its clients the following selection of product development support services: Pharmacological-Toxicological, Pharmaceutical Development, Clinical Trials, Regulatory Affairs. nnn

Salvona Technologies Logo
Salvona Technologies

The mission statement of Salvona is to enhance people's quality of life through cutting-edge technology and the use of environmentally friendly materials and processes. Salvona has focused on developing new and advanced encapsulation and delivery systems to bridge technology gaps as well as to develop tools required to create new products that perform better, are cost effective and are environmentally friendly.

G
Gel Med Sciences

GelMed Sciences, Inc. is commercializing three new agriculture product inventions initially developed by the Penn State University Research Foundation (PSRF). The company's offerings include a Poultry Feed Withdrawal Supplement (PFWS), a Livestock Genetic Marker, and a Gel Drug Delivery Systems which all aim to improve quality and/or output of agricultural products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.